Bluestar Genomics, a San Diego, CA-based company developing epigenomic approaches to early cancer detection, raised $70m Series C funding.
The round was led by current investor Mattias Westman, founding partner of Prosperity Capital Management, with participation from Pathology Asia Holdings Pte Ltd, an independent medical diagnostics group in Southeast Asia, as well as a venture fund based in San Francisco, CA, and a large, diversified asset manager on the west coast, among others.
Led by Samuel Levy, Ph.D., chief executive, and chief scientific officer, Bluestar Genomics develops next-generation epigenomic approaches to detect deadly cancers, like pancreatic, early when curative therapies are possible.
Founded based on the work of Dr. Stephen Quake, the company combines novel epigenomic technologies with its innovative machine learning architecture to tackle the most urgent challenges such as cancer detection.
Separately, the company has announced the expansion of its Scientific Advisory Board, with the appointment of Drs. Felix Feng, professor of radiation oncology, urology, and medicine, University of California San Francisco, and Craig Venter, Ph.D., chairman and CEO of the J. Craig Venter Institute. With the new appointment, Feng and Venter are joining Alan Ashworth, Ph.D., FRS, president, Helen Diller Comprehensive Cancer Center, University of California, San Francisco.